Key result
Ticagrelor monotherapy reduced clinically relevant bleeding compared to DAPT in patients undergoing complex PCI.
Why the study?
Does ticagrelor monotherapy reduce bleeding without increasing ischemic events compared to dual antiplatelet therapy in patients undergoing complex PCI?
Does ticagrelor monotherapy reduce bleeding without increasing ischemic events compared to dual antiplatelet therapy in patients undergoing complex PCI?
Answers are grounded in this paper and cite their sources.
In patients undergoing complex PCI, dropping aspirin and continuing ticagrelor monotherapy after 3 months of DAPT significantly reduces bleeding without increasing ischemic events.
Dual antiplatelet therapy (DAPT) remains the therapeutic cornerstone in post-percutaneous coronary intervention (PCI) patients; however, its duration has not been conclusively established despite large number of trials. The ideal solution should be balancing benefits (events reduction) and risks (bleeding) based in patient’s characteristics and risk factors.1 Evidence shows that complex PCI patients are at a higher risk for major ischaemic events,2,3 a risk that tends to be greater as procedural complexity increases,4 so DAPT of increased duration might overcome this higher risk. On the other hand, complex PCI patients exhibit increased bleeding risk per se,3 a fact that raises the question whether a prolonged DAPT would mitigate ischaemic risks without compromising safety. The recently published TWILIGHT-COMPLEX study5 offers additional information to solve this Goldilocks dilemma: Too short DAPT increases ischaemic events, too long duration increases bleeding. The trials hitherto investigating duration of DAPT studies were dropping the P2Y12 inhibitor after some months and maintaining aspirin monotherapy for life. The main TWILIGHT trial evaluated the safety and efficacy of the novel approach of DAPT (ticagrelor + aspirin) vs. dropping aspirin while maintaining ticagrelor monotherapy, i.e. dropping aspirin.6 Of 9006 patients enrolled, 7119 patients without major bleeding or ischaemic events were kept on ticagrelor and randomized to 12 months of aspirin or placebo.6 The primary endpoint was Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding, and happened less frequently in the ticagrelor monotherapy arm [4% vs. 7.1%; hazard ratio (HR) = 0.56 (0.45–0.68), P < 0.001].6 Importantly, this enhanced safety was not at the expense of reduced efficacy because there was no difference in ischaemic endpoints of cardiovascular death, myocardial infarction, or stroke (3.4% in each group).6 However, these results left many interventional cardiologists wondering if ticagrelor monotherapy could be applicable to the more challenging situation of complex PCI given the increased risk of ischaemic events. The TWILIGHT-COMPLEX study was specifically designed to address that concern. TWILIGHT-COMPLEX5 is a post hoc analysis of outcomes involving the from TWILIGHT who underwent complex PCI. Specifically, complex PCI was defined as any of the following: three vessels treated, ≥3 lesions treated, total stent length >60 mm, bifurcation with two stents implanted, atherectomy device use, left main PCI, surgical bypass graft, or chronic total occlusion as target lesions. These PCIs should be considered quite complex given that 52% of the patients exhibited total stent length >60 mm. Among 7119 patients randomized in the parent TWILIGHT trial, complex PCI was performed in 2342 patients. The rate of primary endpoint (clinically relevant bleeding BARC type 2, 3, or 5) was significantly lower at 12 months of follow-up in the ticagrelor monotherapy group than in DAPT group [4.2% vs. 7.7%; HR 0.54 (0.38–0.76), P < 0.001].5 Severe or fatal bleeding (i.e. BARC type 3 and 5) was also reduced in the ticagrelor monotherapy group, and the bleeding reduction was constant irrespective of the bleeding definition (TIMI, GUSTO, or ISTH). Importantly, this major benefit was achieved at no cost in ischaemic events nor stent thrombosis.5 In the sensitivity analysis, the bleeding benefit and lack of ischaemic harm from ticagrelor monotherapy were consistent regardless of which specific criteria for complex PCI a patient had (in fact, atherectomy seemed to benefit more from ticagrelor monotherapy) or how many of them.5 Since the TWILIGHT-COMPLEX was a post hoc analysis, randomization was not stratified by complex PCI status and multiplicity was not accounted for, thereby increasing the chance for a Type 1 error. Therefore, these findings should be considered hypothesis-generating. However, other studies support these benefits of ticagrelor monotherapy. These findings are in line with a recent secondary analysis from the GLOBAL-LEADERS trial7 that investigated DAPT for 1 month followed by 23 months of ticagrelor monotherapy vs. a standard strategy consisting of 12 months of DAPT plus 12 months of aspirin monotherapy (despite the lack of placebo blinding or clinical event committee adjudication of this latter study), and with a post hoc subanalysis of the TWILIGHT trial in diabetic patients.8 The most solid confirmation of the safety and efficacy of ticagrelor monotherapy comes from an independent clinical trial, the TICO study, which was recently presented at the Virtual ACC Scientific Conference 2020. A total of 3056 acute coronary syndrome patients undergoing PCI were randomized to 9 months of ticagrelor monotherapy (after 3 months of DAPT), or 12 months of DAPT; of note, this is identical strategy as in TWILIGHT. The primary endpoint (net adverse clinical events or NACE combining the risk of ischaemia and severe bleeding) was lower in the ticagrelor monotherapy [3.9% vs. 5.9%, HR 0.66 (0.48–0.92), P = 0.01]. This improvement in NACE was at the expense of a 44% reduction in major bleeding in the ticagrelor monotherapy arm (1.7% vs. 3%, P = 0.02), while ischaemic events were not different in both arms. The main limitation of TICO is that it was open-label trial and not placebo-controlled, but the independent adjudication of clinical outcomes and the fact that two independent clinical trials (TWILIGHT and TICO) show identical results supports the validity of the data. The key question is how to reconcile these data of the benefits with ticagrelor monotherapy (as observed in TWILIGHT and TICO) vs. previous clinical trials demonstrating the superiority of longer DAPT (less ischaemic events albeit with more bleeding), such as PEGASUS9 (aspirin vs. aspirin + ticagrelor), THEMIS10 (aspirin vs. aspirin + ticagrelor in stable CAD and T2DM), CHARISMA11 [aspirin vs. aspirin + clopidogrel in stable coronary artery disease (CAD)], and even COMPASS12 (aspirin vs. aspirin + anticoagulation with rivaroxaban instead of DAPT). There are two key differences between these studies and TWILIGHT. First, patients in the TWILIGHT study received second-generation stents, which are much safer compared to older stents. Second and most important, in the earlier studies showing the benefits of DAPT, it was the P2Y12 inhibitor (the potent antiplatelet agent) that was dropped while aspirin (the weak antiplatelet drug) was kept; TWILIGHT was the first major randomized trial keeping the strong P2Y12 inhibitor and discontinuing aspirin instead. This pathophysiological explanation is supported by a mechanistic substudy of the TWILIGHT trial;13 using the Badimon chamber (the gold-standard method to evaluate blood thrombogenicity14) this study indicated that both ticagrelor monotherapy and ticagrelor + aspirin exhibited similar overall thrombus formation under dynamic flow conditions while the DAPT showed reduced platelet activity in response to arachidonic acid.13 These observations suggest that aspirin does not enhance the global antithrombotic effect of ticagrelor, which explains the similar major adverse cardiovascular events incidence in both groups, while the reduced arachidonic acid-induced platelet aggregation may explain the additional bleeding in the DAPT. This suggests that it is maintaining the potent antithrombotic agent ticagrelor which preserves the ischaemic benefits while dropping the aspirin what reduces bleeding, hinting that aspirin does not add benefits even in the complex patients, just bleeding. One limitation of the TWILIGHT6 study is that patients at high bleeding risk were not studied as patients who bled during the 3 months DAPT were not randomized. Another limitation is the need to discontinue ticagrelor due to dyspnoea and whether surgeons can be convinced to operate on patients on ticagrelor monotherapy. The TWILIGHT trial opens some questions regarding translational research. Coronary flow reserve is a powerful prognostic marker in coronary disease;15 given that ticagrelor cause vasodilatation induced via adenosine, it is very tempting to speculate that part of the benefits are mediated via enhanced myocardial perfusion and not only via antithrombotic effect, but this question remains unanswered for the moment. One question that remains is whether the switch to monotherapy has to be at 3 months, and whether it could be adequate to stop aspirin even earlier. The rationale for 3 months in TWILIGHT was that it allowed clinicians to see whether their patients would tolerate ticagrelor, but this amount of time might probably be shortened. Therefore, we have not solved the Goldilocks dilemma yet (‘not too long but not too short duration of DAPT’). In summary, TWILIGTH-COMPLEX5 suggests that a regimen of ticagrelor monotherapy (after an initial 3 months of DAPT) will significantly lower clinically-relevant bleeding without increasing the risk of ischaemic events compared to those continuing on DAPT, but more research is needed to solve the Goldilocks quandary. Conflict of interest: none declared. Biography: Carlos G. Santos-Gallego, MD is a cardiologist working at the Atherothrombosis Research Unit at Mount Sinai Hospital in New York City. He graduated summa cum laude from Complutense Unviersity in Madrid. He completed his Cardiology Fellowship at Fundación Jiménez Díaz Hospital in Madrid and obtained the SANITAS Award to the Best Fellow of all specialities in all Spain, endorsed by the Spanish Ministry of Health and the Spanish Ministry of Education. He joined the Atherothrombosis Research Unit at Mount Sinai Hospital with a special focus in thrombosis and lipoproteins, for which he leveraged his expertise in non-invasive imaging and animal models to evaluate novel pathways and therapies for atherosclerosis development. He subsequently became interested in cardiomyopathies, both in myocardial ischaemia–reperfusion injury and heart failure, working in animal models and with human patients. He has demonstrated the benefits of the sphingosine-1-phosphate pathway in ameliorating myocardial ischaemia–reperfusion injury. He has determined the mechanism of benefit of SGLT2 inhibitors in heart failure as a shift in myocardial metabolism away from glucose consumption towards the utilization of fatty acids and ketone bodies. He is currently investigating the efficacy of the treatment with SGLT2 inhibitors for heart failure, other cardiomyopathies, and for renal diseases. He has obtained the Research Award by the Royal Academy of Pharmacy in Spain. Biography: Juan Badimon, PhD, FAHA, FACC, is Professor of Medicine/Cardiology and Director of the Atherothrombosis Research Unit at the Mount Sinai Hospital and the Icahn School of Medicine at Mount Sinai, New York City, NY, USA. He obtained his PharmD at the University of Barcelona and his PhD at the High Council Scientific Research, Barcelona. He has worked at Mayo Clinic (Rochester, MN, USA), Massachusetts General Hospital, Boston, and Mount Sinai Hospital, NYC. His first area of interest is the thrombotic effects occurring on atherosclerosis; he developed the Badimon chamber, which is the gold-standard technique to evaluate overall thrombus formation under dynamic flow conditions. His group investigates the thrombotic potential of atheroma plaque and how to counter it by developing novel antiplatelet and anticoagulant drugs. His second area of research is lipoproteins (he was the pioneer in demonstrating experimentally the benefits of HDL) and atherosclerosis, especially with evaluation by non-invasive imaging. His latest area of interest is heart failure and its treatment using SGLT2 inhibitors.
No takes yet. Share an insight, caveat, or question.
Santos‐Gallego et al. (2020) conducted an editorial in complex PCI (n=2,342). Ticagrelor monotherapy vs. DAPT was evaluated on clinically relevant bleeding BARC type 2, 3, or 5 (HR 0.54, 95% CI 0.38-0.76, p=< 0.001). Ticagrelor monotherapy reduced clinically relevant bleeding compared to DAPT in patients undergoing complex PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: